Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Authors
Keywords
-
Journal
BIODRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-13
DOI
10.1007/s40259-023-00626-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Computational and artificial intelligence-based methods for antibody development
- (2023) Jisun Kim et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework
- (2023) Beate Bittner Expert Opinion on Drug Delivery
- High concentration formulation developability approaches and considerations
- (2023) Jonathan Zarzar et al. mAbs
- Nothing about us should be without us
- (2023) Maria Piggin Lancet Haematology
- Patients as research partners in preference studies: learnings from IMI-PREFER
- (2023) Meredith Y. Smith et al. Research Involvement and Engagement
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tutorial: Statistical analysis and reporting of clinical pharmacokinetic studies
- (2022) Ann‐Cathrine Dalgård Dunvald et al. CTS-Clinical and Translational Science
- Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
- (2022) Rajanikanth Madabushi et al. PHARMACEUTICAL RESEARCH
- Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- (2022) Emmanuel Donnadieu et al. Journal for ImmunoTherapy of Cancer
- Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
- (2022) Erin K. McCreary et al. JAMA Network Open
- Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
- (2022) Matias Rodrigo Chacon et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
- (2022) Romy Mosch et al. Frontiers in Immunology
- Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up
- (2022) Mustafa N. Yenerel et al. ADVANCES IN THERAPY
- A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
- (2022) Conor McCloskey et al. Pharmacoeconomics-Open
- Development of Therapeutic Proteins for a New Subcutaneous Route of Administration after the Establishment of Intravenous Dosages: A Systematic Review
- (2022) Zhenhua Xu et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Modeling large-volume subcutaneous injection of monoclonal antibodies with anisotropic porohyperelastic models and data-driven tissue layer geometries
- (2022) Mario de Lucio et al. Journal of the Mechanical Behavior of Biomedical Materials
- P6 EMA/EUnetHTA Qualification of the IMI PREFER Patient Preference Framework and Points to Consider for Method Selection: Key Experiences, Outcomes, Value and Implications
- (2022) L Barbier et al. VALUE IN HEALTH
- Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
- (2021) Nicole L. Jarvi et al. BIODRUGS
- Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
- (2021) Issam S. Hamadeh et al. Clinical Lymphoma Myeloma & Leukemia
- Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
- (2021) Yu Tang et al. Pharmaceutics
- Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
- (2021) Zhigang Wang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Evaluation of Large Volume Subcutaneous Injection Tissue Effects, Pain, and Acceptability in Healthy Adults
- (2021) Wendy D Woodley et al. CTS-Clinical and Translational Science
- Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
- (2021) Joyce O'Shaughnessy et al. EUROPEAN JOURNAL OF CANCER
- The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018
- (2021) Stephen J. Richards et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
- (2021) Mary Slavcev et al. ClinicoEconomics and Outcomes Research
- Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma
- (2021) E. Bridget Kim et al. BLOOD
- Model‐Informed Drug Development Approaches to Assist New Drug Development in the COVID‐19 Pandemic
- (2021) Ye Xiong et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors
- (2020) Ping Hu et al. AAPS Journal
- Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence Studies in Order to Demonstrate Comparability?
- (2020) William J. Lambert AAPS Journal
- Injectable Combination Product Development: Facilitating Risk-Based Assessments for Efficiency and Patient Centric Outcomes
- (2020) Fran DeGrazio et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
- (2020) Chiara Whichello et al. HEALTH POLICY
- The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
- (2020) Anna Vaisman-Mentesh et al. Frontiers in Immunology
- Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects
- (2020) Wendy D Woodley et al. CTS-Clinical and Translational Science
- Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- (2020) Antoinette R Tan et al. LANCET ONCOLOGY
- Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
- (2020) Anja St Clair-Jones et al. Rheumatology and Therapy
- Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma
- (2019) Saad Z. Usmani et al. BLOOD
- Helping patients help themselves: A systematic review of self-management support strategies in primary health care practice
- (2019) Sarah Dineen-Griffin et al. PLoS One
- The importance of early identification of infusion-related reactions to monoclonal antibodies
- (2019) Macarena C Cáceres et al. Therapeutics and Clinical Risk Management
- Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
- (2019) Di Bei et al. CANCER SCIENCE
- Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
- (2018) A. Brekkan et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model
- (2018) Ninad Varkhede et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Adverse events in patients in home healthcare: a retrospective record review using trigger tool methodology
- (2018) Kristina Görel Ingegerd Schildmeijer et al. BMJ Open
- Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
- (2018) Beate Bittner et al. BIODRUGS
- Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?
- (2018) Satish K. Singh et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Infusion-related reactions to rituximab: frequency, mechanisms and predictors
- (2018) Franciane Paul et al. Expert Review of Clinical Immunology
- Roadmap and strategy for overcoming infusion reactions to nanomedicines
- (2018) Janos Szebeni et al. Nature Nanotechnology
- Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
- (2017) Lora Hamuro et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
- (2016) M. Rummel et al. ANNALS OF ONCOLOGY
- Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
- (2016) Khilna Patel et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
- (2015) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
- (2015) Sarit Assouline et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
- (2015) Angelica L. Quartino et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Model-based clinical drug development in the past, present and future: a commentary
- (2014) Holly Kimko et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- (2014) Antonio Salar et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
- (2014) Andrew Davies et al. LANCET ONCOLOGY
- A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
- (2014) Jasmine P Davda et al. mAbs
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic Model
- (2013) Liang Zhao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- The questionable use of unequal allocation in confirmatory trials
- (2013) S. P. Hey et al. NEUROLOGY
- Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen
- (2012) B. Bittner et al. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
- Home medication management practices and associated factors among patients with selected chronic diseases in a community pharmacy in Uganda
- (2012) Joan N Kalyango et al. BMC HEALTH SERVICES RESEARCH
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
- (2012) Chris Wynne et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis
- (2012) Jai S Perumal et al. Multiple Sclerosis Journal
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started